Longevity/Performance/Heart
NAD+ Precursors
Compounds like NMN and NR that raise NAD+ levels, with emerging evidence for physical performance and modest cardiovascular effects in older adults.
NAD+ Precursors
Compounds like NMN and NR that raise NAD+ levels, with emerging evidence for physical performance and modest cardiovascular effects in older adults.
38
C
evidenceCaution
riskProven Benefits
01Elevates blood NAD+ levels
02Improves physical performance
03May lower blood pressure
Chemical Forms
Recommended
- Nicotinamide riboside (NR)
- Nicotinamide mononucleotide (NMN)
Avoid
- Direct NAD+ (destroyed by stomach acid, no bioavailability)
- Nicotinamide (niacinamide) — can inhibit sirtuins at high doses
Expert Note
NR and NMN are the most efficient oral precursors; they bypass the rate-limiting NAMPT enzyme. Oral NAD+ is hydrolyzed by gastric acid and does not reach circulation intact. Standard niacinamide may raise NAD+ but requires higher doses and can blunt sirtuin activity.
Protocol
Amount
250-1000 mg
Frequency
Once daily
When
Morning, with or without food — consistency matters more than timing.
Condition-Based Dosing
General wellness / anti-aging
250-500 mg daily
Older adults targeting physical function
500-1000 mg daily
Elevated blood pressure or vascular stiffness
1000-2000 mg daily
Safety & Limits
Upper Safe Limit
2000 mg/day (highest dose studied in 12-week RCTs; no official UL established)
Cycling
Safe for continuous use
Contraindications
Active cancer or history of cancer — theoretical concern that NAD+ may fuel tumor growth
Pregnancy or breastfeeding — insufficient safety data
Chemotherapy or radiation therapy — NAD+ precursors may theoretically protect cancer cells
Synergies
Trimethylglycine (TMG)
NR/NMN metabolism consumes methyl groups; TMG or B-vitamins may help maintain healthy homocysteine levels.
Avoid Combining With
- ✕Alcohol (depletes NAD+ and B-vitamins, counteracting supplementation)
- ✕High-dose niacinamide (competes for NAD+ synthesis pathways and may inhibit sirtuins)
- ✕Chronic inflammation (accelerates CD38-driven NAD+ consumption)
Updated Invalid Date